Pathophysiologie ya kansere ya prostate ke tendula mambu yina ke salaka nde maladi yango kukuma ngolo.
Kansere ya prostate kele kansere ya mbi yina ke basikaka na baselile ya prostate, yina kele na nsi ya kisumbula ya nene ya babakala.
Prostate kebasisaka masa ya kuvukisa nitu yina kedisaka mpi kenataka bambuma ya babakala.
Bantu ke zabaka ve mbote-mbote kikuma yina ke salaka nde muntu kukuma ti kansere ya prostate, kansi bo me zaba nde mambu mingi ke salaka nde muntu kukuma ti kansere ya prostate.
Mu mbandu, bamvula, mambu ya dibuta, mpusu ya nitu, mpi ba mutation ya nkaka ya ke vandaka na baselile.
Kansere ya prostate ke monanaka mingi na babakala yina me kuma bambuta, mingi-mingi bayina me luta bamvula 65.
Dyaka, babakala yina dibuta na bo kevandaka ti kansere ya prostate kevandaka na kigonsa ya ngolo ya kubela yo, mutindu mosi mpi babakala ya Afrika ya Amerika mpi bayina mekatukaka na Caraïbes.
Kansere ya prostate ke basikaka ntangu baselile ke yelaka mpi ke kabwanaka kukonda lutwadisu.
Yo lenda salama sambu na kubeba ya ba gènes yina ke salaka nde ba gènes ya nkaka yina ke salaka nde maladi kuyela mingi to ba gènes yina ke kangaka maladi kuyela ve.
Bima yai ya kebalukaka lenda sala nde baselile kuyela kukonda lutwadisu, ebuna yo nata na kubasika ya tumeur.
Kana kansere ke yela, yo lenda kota na baselile ya nkaka ya kele pene-pene, mu mbandu na pima, na mukongo, mpi na ba ganglion ya nene.
Na bantangu ya nkaka, baselile ya kansere lenda basika na tumeur ya ntete mpi kupanzana na bitini ya nkaka ya nitu na nzila ya menga to ya baselile ya nkaka ya nitu.
Kana kansere me yalumuka, yo lenda vanda mpasi na kusansa yo.
Kansere ya prostate lenda kuma mpi ngolo kana muntu ke nwa bima yina ke salaka nde nitu kusala kisalu mbote, mingi-mingi hormone ya androgène (testostérone).
Testostérone lenda pusa baselile ya kansere ya prostate na kuyela, mpi bankisi mingi ya bo kesadilaka sambu na kubelula kansere ya prostate kevandaka ti lukanu ya kufyotuna ntalu ya hormone yai to kukanga bupusi na yo.
Na bunkufi, maladi ya kansere ya prostate ke vandaka ti mutindu ya kuyela mpi kukabwana ya baselile yina ke vandaka ve na ndonga na kati ya prostate, yina lenda vanda ti bupusi ya ba gènes, ba hormone, mpi mambu ya ke vandaka na nzyunga.
Kubakisa mutindu maladi ke salamaka kele mfunu sambu na kuzaba mutindu ya mbote ya kusansa yo mpi kubelula yo mbote.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
['Disclaimer: mambu ya kimunganga']
['Site Internet yai kele kaka sambu na kulonga mpi kupesa bansangu, kansi yo kele ve sambu na kupesa bandongisila ya minganga to kusadila bantu ya nkaka kisalu.']
['Bo fwete sadila ve bansangu yina bo kepesa sambu na kuzaba to kubelula maladi mosi buna, mpi bantu yina kesosa bandongisila ya kimunganga fwete solula ti munganga yina kele ti nswa ya kusala kisalu yina.']
['Tala nde, ba-apareyi yina ke pesaka bamvutu na bangiufula ke vandaka ve mbote ntangu bo ke sadilaka ntalu, mu mbandu ntalu ya bantu yina bo me zaba nde bo ke belaka maladi mosi buna.']
['Sosa ntangu yonso bandongisila ya munganga to ya muntu ya nkaka ya me zaba kisalu ya kusansa bantu sambu na maladi na nge. Kuvila ve bandongisila ya munganga to kusukinina ve na kusosa yo sambu na mambu ya nge me tanga na site Internet yai. Kana nge ke yindula nde nge kele ti maladi ya ngolo, binga 911 to kwenda nswalu na lupitalu ya me finama. Site Internet yai to mutindu nge ke sadila yo ke sala ve nde nge kuma nduku ya munganga to nkengi ya maladi.']
['Banswa ya kusonika']
['Nsiku ya Banswa ya Bansoniki ya Internet ya mvu 1998, 17 U.S.C. § 512 (DMCA) ke pesa nswa na bantu yina kele ti banswa ya bansoniki ya ke kwikila nde mambu yina ke monana na Internet ke fwa banswa na bo na nsi ya nsiku ya banswa ya bansoniki ya États-Unis. ']
['Kana nge ke mona nde mambu ya nge ke tanga na site Internet na beto to na baservice na beto ke fwa banswa na nge, nge (to muntu yina ke twadisaka nge) lenda tindila beto mukanda sambu na kulomba nde beto katula yo to kukanga nzila na nge ya kusadila yo.']
['Bo fwete tinda bansangu na mukanda na nzila ya email (tala na "Kutuba na beto" sambu na kuzaba adresi ya email).']
['Nsiku ya DMCA ke lomba nde na mukanda na nge ya ke tubila nde bo me fwa nsiku ya banswa ya bantu, nge sonika mambu yai: (1) mutindu ya kutendula kisalu yina bo me fwa nsiku; (2) mutindu ya kutendula mambu yina bo me fwa nsiku mpi bansangu yina ta sadisa beto na kuzaba kisika yina mambu yango kele; (3) bansangu ya nge lenda sadila sambu na kusolula ti nge, tanga mpi adresi na nge, nimero ya telefone mpi adresse ya e-mail; (4) mambu ya nge me tuba nde nge ke kwikila nde mambu yina nge ke tuba kele ve na nswa ya munkwa-kisalu to muntu yina me pesa nswa na yo to na nsiku ya leta.']
['5) na nima ya kupesa nzikisa na mukanda yina nge me sonika, nge fwete ndima nde mambu yina nge me tuba kele ya kieleka mpi nde nge kele ti nswa ya kusadila banswa yina bo me bebisa.']
['mpi (6) kidimbu ya muntu yina kele ti nswa ya kubasisa yo to ya muntu yina kele ti nswa ya kusala mambu na zina na yandi. ']
['Kana nge pesa ve bansangu yai yonso, yo lenda sala nde bo sala ve mambu nswalu.']
['Kusolula']
['Beno tindila beto email kana beno kele na ngyufula to ngindu.']
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Na kiteso ya']
['BioMedLib kesadilaka ba ordinatere ya bo mesalaka bo mosi (ba algorithme ya kulonguka na masini) sambu na kubasisa bangyufula ti bamvutu.']
['Beto me yantika ti mikanda ya kimunganga ya bamilio 35 ya PubMed/Medline mpi basite ya Internet ya RefinedWeb.']
